MX2012012941A - Nuevas composiciones oftalmicas. - Google Patents

Nuevas composiciones oftalmicas.

Info

Publication number
MX2012012941A
MX2012012941A MX2012012941A MX2012012941A MX2012012941A MX 2012012941 A MX2012012941 A MX 2012012941A MX 2012012941 A MX2012012941 A MX 2012012941A MX 2012012941 A MX2012012941 A MX 2012012941A MX 2012012941 A MX2012012941 A MX 2012012941A
Authority
MX
Mexico
Prior art keywords
ophthalmic compositions
novel ophthalmic
solution
novel
prostaglandin
Prior art date
Application number
MX2012012941A
Other languages
English (en)
Inventor
Arindam Halder
Ajay Jaysingh Khopade
Subhas Balaram Bhowmick
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2012012941A publication Critical patent/MX2012012941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una solución oftálmica que comprende cantidad terapéuticamente efectiva de una prostaglandina o su análogo y excipiente(s) en agua en un vehículo farmacéuticamente aceptable, caracterizado porque la solución está libre de un tensioactivo.
MX2012012941A 2010-05-07 2011-05-06 Nuevas composiciones oftalmicas. MX2012012941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1448MU2010 2010-05-07
PCT/IN2011/000320 WO2011138801A1 (en) 2010-05-07 2011-05-06 Novel ophthalmic compositions

Publications (1)

Publication Number Publication Date
MX2012012941A true MX2012012941A (es) 2013-07-29

Family

ID=44903675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012941A MX2012012941A (es) 2010-05-07 2011-05-06 Nuevas composiciones oftalmicas.

Country Status (10)

Country Link
US (1) US20130267591A1 (es)
EP (1) EP2566453A4 (es)
JP (1) JP2013525508A (es)
KR (1) KR20130139748A (es)
CN (1) CN102970973A (es)
BR (1) BR112012028437A2 (es)
CA (1) CA2798923A1 (es)
MX (1) MX2012012941A (es)
TW (1) TW201204390A (es)
WO (1) WO2011138801A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011079062A1 (de) * 2011-05-02 2012-11-08 Beiersdorf Ag Behältnisse für kosmetische und dermatologische Produkte
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP2841104A1 (en) 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
FI2887923T3 (fi) 2012-08-24 2023-06-30 Sun Pharmaceutical Ind Ltd Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito
CA2932618A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure
US20150335704A1 (en) 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20180333352A1 (en) * 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
SG11201906729RA (en) 2016-02-29 2019-08-27 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
HUE052747T2 (hu) * 2018-07-12 2021-05-28 Nicox Sa Szemészeti készítmények, amelyek tartalmaznak nitrogén-monoxidot felszabadító prosztamidot
TW202320815A (zh) * 2021-09-30 2023-06-01 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203103T3 (es) * 1998-04-07 2004-04-01 Alcon Manufacturing Ltd. Composiciones oftalmicas gelificantes que contienen goma xantana.
WO2000004898A1 (en) * 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2001081048A (ja) * 1999-09-10 2001-03-27 Wakamoto Pharmaceut Co Ltd 眼圧降下剤
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
JP4698020B2 (ja) * 2000-12-19 2011-06-08 テルモ株式会社 薬剤収納容器
WO2005018646A1 (ja) * 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
CN101516332B (zh) * 2006-09-21 2012-12-19 爱尔康研究有限公司 自身防腐的水性药物组合物
JP2008120764A (ja) * 2006-11-15 2008-05-29 Nippon Tenganyaku Kenkyusho:Kk プロスタグランジン水性点眼剤
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP5243064B2 (ja) * 2008-03-03 2013-07-24 テルモ株式会社 医療用容器
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

Also Published As

Publication number Publication date
US20130267591A1 (en) 2013-10-10
EP2566453A1 (en) 2013-03-13
EP2566453A4 (en) 2014-05-07
CA2798923A1 (en) 2011-11-10
KR20130139748A (ko) 2013-12-23
BR112012028437A2 (pt) 2016-07-19
JP2013525508A (ja) 2013-06-20
TW201204390A (en) 2012-02-01
WO2011138801A1 (en) 2011-11-10
CN102970973A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
MX2012012941A (es) Nuevas composiciones oftalmicas.
PH12020550759A1 (en) Compositions and methods of use of phorbol esters
IN2012DN06581A (es)
MX2011012739A (es) Derivados fluorados de aminotriazol.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012214029A8 (en) Rorgammat inhibitors
MY159820A (en) Macrocyclic hepatitis c serine protease inhibitors
MX2013001677A (es) Formulaciones estables de linaclotida.
MY183312A (en) Pharmaceutical formulation
WO2009063222A3 (en) Solid compositions
WO2011156337A3 (en) Macrocyclic hepatitis c serine protease inhibitors
WO2012092409A3 (en) Macrocyclic hepatitis c serine protease inhibitors
TN2012000279A1 (en) Processes for the manufacture of a pharmaceutically active agent
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
IN2012DN00765A (es)
WO2011079193A3 (en) Preparation of bendamustine and its salts
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MY160383A (en) Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
WO2012064302A3 (en) Improved montelukast formulations
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
MX2013008635A (es) Mejoras de y relacionadas con composiciones.
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
WO2011128699A3 (en) Novel process for the preparation of sunitinib

Legal Events

Date Code Title Description
FA Abandonment or withdrawal